Arcus Biosciences Inc
RCUS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.33B
Close$
$-22.32
220.4% downside
Current Fair Value
220.4% downsideOvervalued by 220.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.33 Billion |
|---|---|
| Enterprise Value | $2.31 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.29 |
| Beta | 0.81 |
| Outstanding Shares | 126,100,000 |
Return
| Return on Equity | -97.41% |
|---|---|
| Return on Assets | -48.92% |
| Return on Invested Capital | -60.61% |
Valuation & Multiples
| P/E Ratio | -4.72 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 6.18 |
| Enterprise Value to Revenue | 19.78 |
| Enterprise Value to EBIT | -5.26 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.89
Average shareholder expectationRevenue Estimate
$21.98 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$-0.89
Average shareholder expectationRevenue Estimate
$7.58 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 12.83% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.25%▼ 97.78% |
|---|---|
| Total Invested | $8.17M▼ 99.79% |
| Investors Holding | 30▼ 210.00% |
ESG Score
No data